A randomized, double-blind, multicenter phase 3 study in patients with moderately to severely active ulcerative colitis (UC) to compare the efficacy, safety and immunogenicity of PB016 and Entyvio® for the induction and maintenance of clinical response and remission. (UCESIVE) - NI

Polpharma Biologics S.A.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

阶段: 3 期
状态: 招募中
发起方: Polpharma Biologics S.A.

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. At Screening, females of childbearing potential must be non-pregnant and non-lactating; or females should be of non-childbearing potential (either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year post menopausal [amenorrhea duration of 12 consecutive months]) non-pregnancy will be confirmed for all females of childbearing potential by a serum pregnancy test conducted at Screening.2.Female patients of childbearing potential, with a fertile male sexual partner, must use adequate contraception from Screening until 18 weeks after the last dose of study drug. Adequatecontraception is defined as using hormonal contraceptives or an intrauterine device, combined with at least one of the following forms of contraception: a diaphragm or cervical cap, or a condom. Total abstinence from heterosexual activity, inaccordance with the lifestyle of the patient, is acceptable.3. Male patients who are sexually active with women of childbearing potential agree they will use adequate contraception from Screening until 90 days after the last dose of study drug if not surgically sterilized at least 6 months before Screening (with a post-vasectomy semen analysis negative for sperm). Male patients must not donate sperm until 90 days after the last dose of study drug. Adequate contraception for the male patient and his female partner of childbearing potential is defined as using hormonal contraceptives or an intrauterine device, combined with at least one of the following forms of contraception: a diaphragm or cervical cap, or a condom. Total abstinence from heterosexual activity, in accordance with the lifestyle of the patient, is acceptable.4. Diagnosis of moderate to severe UC established at least 6 months prior to Screening by clinical and endoscopic evidence, corroborated by a histopathology report and confirmed by the Investigator.5. Moderately to severely active UC as determined by a complete Mayo score of 6 to 12 with an endoscopic sub-score is more than or equal to 2, confirmed by a central reader within 28 days prior to randomization.6. Evidence of UC extending proximal to the rectum (is greater than or equal to 15 cm of involved colon).7. Patients with extensive colitis or pancolitis of greater than 8 years duration or left-sided colitis of greater than 12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months of the initial Screening Visit (may be performed during Screening).8. Patients with a family history of colorectal cancer, personal history of increased colorectal cancer risk, age greater than 45 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during Screening).

排除标准

•1. Previous exposure to vedolizumab (Entyvio® or any other investigational vedolizumab containing product).
•2. Female patients who are lactating or have a positive serum pregnancy test during the Screening Period or a positive urine pregnancy test on Day 0 prior to study drug administration
•3. Within 30 days prior to randomization, has received any of the following for the treatment of underlying disease:
•a. Non-biologic therapies (e.g., cyclosporine, thalidomide) other than those specifically listed in Inclusion
•Criterion 8.
•b. A non-biologic investigational therapy
•c. An approved non-biologic therapy in an investigational protocol
•4. Has received any investigational or approved biologic or biosimilar agent within 60 days or 5 half-lives prior to randomization (whichever is longer)
•5. Has had prior exposure to approved or investigational anti-integrin antibodies (e.g., natalizumab, efalizumab, etrolizumab, AMG-181, anti-MAdCAM-1 antibodies) or antiCD20 antibodies (e.g., rituximab)
•6. Evidence of abdominal abscess or toxicmegacolon at the Screening Visit.
•7. Extensive colonic resection, subtotal or total colectomy
•8. History of ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine
•9. Diagnosis of Crohn’s disease, microscopic colitis, ischemic colitis or indeterminate colitis.
•10. Had any surgical procedure requiring general anesthesia within
•30 days prior to randomization or the patient currently requires or
•is anticipated to require surgical intervention for UC during the
•11. Has any identified congenital or acquired immunodeficiency
•(e.g., common variable immunodeficiency, human
•immunodeficiency virus [HIV] infection, organ transplantation).
•12. Has any live vaccination within 30 days prior to Screening or is
•planning to receive any live vaccination during participation in
•13. Has used a topical (rectal) treatment with (5-ASA) or
•corticosteroid enemas/suppositories within 2 weeks prior to
•randomization unless taken on stable dose for at least 2 weeks
•before randomization
•14. Has any unstable or uncontrolled cardiovascular disorder, heart
•failure moderate to severe (New York Heart Association Class III
•or IV), any pulmonary, hepatic, renal, GI, genitourinary,
•hematological, coagulation, immunological, endocrine/metabolic,
•or other medical disorder that, in the opinion of the Investigator,
•would confound the study results or compromise patient safety
•15. Has received total parenteral nutrition or albumin in the last 30
•days prior to randomization.

研究者

发起方

Polpharma Biologics S.A.

相似试验

招募中

1 期

A study in people with moderately to severely active ulcerative colitis to see how well an investigational treatment called PB016 works and how safe it is compared to a licensed treatment called Entyvio®.ulcerative colitis

CTIS2022-502778-18-00Polpharma Biologics S.A.679

进行中（未招募）

1 期

A randomized, multicenter, double-blind phase 3 study of amcenestrant (SAR439859) plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease - AMEERA-5ER (+), HER2 (-) breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-001824-33-BGSanofi-Aventis Recherche & Développement1,333

进行中（未招募）

1 期

Amcenestrant (SAR439859) plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancerER (+), HER2 (-) breast cancerMedDRA version: 20.0Level: PTClassification code 10006187Term: Breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-001824-33-HUSanofi-Aventis Recherche & Développement1,333

进行中（未招募）

1 期

Amcenestrant (SAR439859) plus palbociclib as first line therapy for patients with ER(+) HER2(-) advanced breast cancer

EUCTR2020-001824-33-FISanofi-Aventis Recherche & Développement1,333

进行中（未招募）

1 期

EUCTR2020-001824-33-ITSANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT1,333